眼科治疗公司
OCUL
6.87
-0.51
-6.91%
眼科治疗公司
US · OCUL
#2978 按市值排名
上市于 1970
6.87
-0.51
-6.91%
实时 - 追踪5344个代码 - 心跳于68秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
增持
- 机构持股总比例上升了0.4个百分点。
机构持股
- 机构持股比例
- 95.06% +0.40pp
- 机构数量
- 307
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期增持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund51.18%
Hedge Fund19.38%
VC/PE Fund15.05%
Family Office/Trust5.63%
Public Company2.09%
Individual/Insider1.20%
Private Company1.05%
Insurance Company0.41%
Government Pension Fund0.26%
Other3.75%
主要股东 截至 2026-06-30
FMR
14.96% · 32.84M 股
Deep Track Capital, LP
8.96% · 19.69M 股
BlackRock
8.82% · 19.38M 股
Avoro Capital Advisors LLC
5.71% · 12.54M 股
Summer Road LLC
5.56% · 12.21M 股
VR Management, LLC
4.71% · 10.35M 股
Vanguard Capital Management, LLC
4.61% · 10.12M 股
T. Rowe Price Group, Inc.
3.47% · 7.62M 股
Logos Global Management, L.P.
2.41% · 5.30M 股
State Street Global Advisors
2.38% · 5.23M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 22次买入 · 28次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Pravin Dugel | Executive Chairperson | 0.36% |
| Antony Mattessich | Chief Executive Officer | 0.18% |
| Richard Lindstrom | Independent Director | 0.11% |
| Donald Notman | Chief Financial Officer | 0.08% |
| Sanjay Nayak | Chief Strategy Officer | 0.08% |
| Jeffrey Heier | Independent Director | 0.07% |
| Peter Kaiser | Chief Medical Advisor of Retina | 0.04% |
| Nadia Waheed | Chief Medical Officer | 0.04% |
| William Link | -- | 0.04% |
| Steve Meyers | Senior Vice President of Commercial | 0.03% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-10-01 | Jeffrey Heier | Independent Director | Intent to Sell (Form 144) | -10,869 | $7.05 |
| 2026-08-30 | Donald Notman | Chief Financial Officer | Open Market Disposition | -1,099 | $10.24 |
| 2026-08-24 | Pravin Dugel | Executive Chairperson | Other Acquisition | +50,092 | -- |
| 2026-08-24 | Pravin Dugel | Executive Chairperson | Other Disposition | -50,092 | -- |
| 2026-08-23 | Jeffrey Heier | Independent Director | Open Market Disposition | -3,296 | $10.78 |
| 2026-08-23 | Peter Kaiser | Chief Medical Advisor of Retina | Open Market Disposition | -3,035 | $10.77 |
| 2026-08-23 | Pravin Dugel | Executive Chairperson | Open Market Disposition | -21,649 | $10.77 |
| 2026-08-23 | Sanjay Nayak | Chief Strategy Officer | Open Market Disposition | -1,897 | $10.78 |
| 2026-06-15 | Pravin Dugel | Executive Chairperson | Other Acquisition | +50,092 | -- |
| 2026-06-15 | Pravin Dugel | Executive Chairperson | Other Disposition | -50,092 | -- |
| 2026-06-09 | William Link | -- | Other Acquisition | +14,000 | -- |
| 2026-06-09 | William Link | -- | Other Derivative Acquisition | +44,000 | $8.74 |
| 2026-06-09 | Merilee Raines | Independent Director | Other Acquisition | +14,000 | -- |
| 2026-06-09 | Merilee Raines | Independent Director | Other Derivative Acquisition | +44,000 | $8.74 |
| 2026-06-09 | Richard Lindstrom | Independent Director | Other Acquisition | +14,000 | -- |
| 2026-06-09 | Richard Lindstrom | Independent Director | Other Derivative Acquisition | +44,000 | $8.74 |
| 2026-06-09 | Adrienne Graves | Director | Other Acquisition | +14,000 | -- |
| 2026-06-09 | Adrienne Graves | Director | Other Derivative Acquisition | +44,000 | $8.74 |
| 2026-06-09 | Leslie Williams | Independent Director | Other Acquisition | +14,000 | -- |
| 2026-06-09 | Leslie Williams | Independent Director | Other Derivative Acquisition | +44,000 | $8.74 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
眼科治疗公司 讨论区 0 条评论